A Phase 1 Study Of Gilteritinib In Combination With Induction And Consolidation Chemotherapy In Patients With Newly Diagnosed Aml: Final Results

Keith W. Pratz,Mohamad Cherry,Jessica K. Altman,Brenda W. Cooper,Jose Carlos Cruz,Joseph G. Jurcic,Mark Levis,Tara Lin,Alexander E. Perl,Nikolai A. Podoltsev,Gary J. Schiller,Jason E. Hill,Angela James,Qiaoyang Lu,Ramon V. Tiu

BLOOD（2020）

引用 26|浏览30

暂无评分

摘要

Background: Gilteritinib, an oral FMS-like tyrosine kinase 3 (FLT3) inhibitor, demonstrated antileukemic responses in patients with FLT3-mutated (FLT3mut+) relapsed/refractory acute myeloid leukemia (AML). We report final results from a phase 1 study of once-daily oral gilteritinib plus intravenous (IV) chemotherapy in patients with newly diagnosed AML.

查看译文

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要